Why the study?
Does single-dose S663V-RBD vaccine improve SARS-CoV-2 specific immune responses in SPF 6-8-week-old female BALB/c mice?
Population
Mice
Comparison
Single-dose S663V-RBD vs licensed BBIBP-CorV
Follow-up
More than 4 months
Authors
Loading...
Does not support clinical adoption of S663V-RBD; leaves open its value as a durable, variant-resistant COVID-19 vaccine platform.
Does single-dose S663V-RBD vaccine improve SARS-CoV-2 specific immune responses in SPF 6-8-week-old female BALB/c mice?
A single-dose engineered AAV6-based SARS-CoV-2 vaccine (S663V-RBD) induces rapid, robust, and long-lasting neutralizing antibodies in mice, outperforming a licensed inactivated vaccine.
Wu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: